Nucleic Acid and Gene Delivery Systems by the Combination of Nanobubbles and Ultrasound

• Date :
• 3    
  0

Overview of Standards Setting for Cell/Gene Therapies-- Case Studies

• Date :
• 3    
  0

Phase IIb Multiple Dose, Non-Viral, Cystic Fibrosis Gene Transfer Clinical Trial

• Date :
• 3    
  0

T cell Product Attributes that Correlate with Clinical Efficacy in B-ALL

• Date :
• 2    
  0

Real-World Challenge: High Upfront Costs for Payers

• Date :
• 2    
  0

Nuclease-free Genome Editing Confers a Hepatocellular Growth Advantage for Corrected Cells in MMA

• Date :
• 2    
  0

Non-Viral Vector Design and Production

• Date :
• 2    
  0

piggyBac Transposons to Cut and Paste DNA

• Date :
• 2    
  0

Overview -Scientific Symposium from the American Society of Gene & Cell Therapy's 22nd Annual Meeting

• Date :
• 2    
  0

Oncolytic Vectors: Understanding their Potential to Treat Cancer

• Date :
• 2    
  0

Gene Therapy for Cardiac Symptoms in Friedreich’s Ataxia

• Date :
• 1    
  0

Pluripotent Cell-Derived T and NK Cells as a Cornerstone Approach for Cancer Immunotherapy

• Date :
• 1    
  0

Real-World Challenge: Innovative Value-Based Agreements - Opportunities and Challenges

• Date :
• 1    
  0

Potential Challenges Throughout the Development Process

• Date :
• 1    
  0

Preparing for Launch and Adjusting the Constant of Evolution in Gene Therapy

• Date :
• 1    
  0

Optimization of HSC Gene Therapy Approaches to Treat Neurometabolic and Neurodegenerative Conditions

• Date :
• 1    
  0

Progress and Challenges of Developing Liver-targeted Gene Therapy for Crigler-Najjar Syndrome

• Date :
• 1    
  0

Protein Nanoparticle Engineering in Vaccine Development

• Date :
• 1    
  0

Real World Challenges: Considerations for Pricing and Value

• Date :
• 1    
  0

Electroporation-Mediated DNA Administration as an Antibody Delivery Platform

• Date :
• 1    
  0

Real-World Challenge: Establishing the Value of Gene Therapy for Patients

• Date :
• 1    
  0

Redirection of T cells against HBV-infected cells

• Date :
• 1    
  0

Re-introducing the Patient Context into Cardiac Drug Discovery Using iPSCs

• Date :
• 1    
  0

Selective Targeting of Mutant Huntingtin Using Stereopure Oligonucleotides

• Date :
• 1    
  0

Small RNA Molecules for RNA Editing Therapy in LCA10 Patients

• Date :
• 1    
  0

Next-generation AAV Vectors

• Date :
• 1    
  0

My 40-year Journey to Develop RNA Based Therapies

• Date :
• 1    
  0

Translating Gene Therapy Medicinal Products into Early Clinical Trials

• Date :
• 1    
  0

Ultrasound Mediated Gene Delivery in Large Animal Models

• Date :
• 1    
  0

Universal Gene-Edited CAR T-Cell Immunotherapy

• Date :
• 1    
  0

Making New Beta Cells by Reprogramming

• Date :
• 0    
  0

Next Generation Oncolytic Immunotherapy

• Date :
• 0    
  0

mRNA Manufacturing

• Date :
• 0    
  0

Moving Towards Commercialization of a Potentially Curative Gene Therapy

• Date :
• 0    
  0

Lipid Nanoparticle Delivery Technology for siRNA and mRNA Therapeutics

• Date :
• 0    
  0

On the Brink of a Treatment Revolution for Inherited Pediatric Neurological Diseases

• Date :
• 0    
  0

RNA-based Drugs Including Delivery of Antibodies and Vaccines Using mRNA

• Date :
• 0    
  0

Synthetic Viruses & Tissue Interactions

• Date :
• 0    
  0

The First FDA Approved RNAi Therapeutic ONPATTRO and Beyond

• Date :
• 0    
  0

The Makings of a Living Drug

• Date :
• 0    
  0

The Prevalence of Adaptive Immunity to Cas9 Proteins

• Date :
• 0    
  0

The Varying Perspectives of the Rare Disease Patient Advocacy Community on RTT

• Date :
• 0    
  0

Theranostics-Guided Oncolytic Virotherapy

• Date :
• 0    
  0

Utilizing Expedited Designations in Moving Toward Market Approval

• Date :
• 0    
  0

Cellular Immunotherapy for Solid Tumors

• Date :
• 0    
  0

Engineered iPSC-derived Lymphocytes for Improved Cancer Therapy

• Date :
• 0    
  0

DNA Nucleases in Gene Editing - "No need for a break?"

• Date :
• 0    
  0

Dissecting and Overcoming Innate Immune Barriers for Efficient Stem Cell Gene Engineering

• Date :
• 0    
  0

Development of EDIT 101, A Gene-editing Approach to Restore Vision Loss in LCA Type 10

• Date :
• 0    
  0

Development of an AAV-based Prophylactic Vaccine for Influenza

• Date :
• 0    
  0

Design, Synthesis, and Application of Antibody Nucleic Acid Analogs as Novel Biopharmaceuticals

• Date :
• 0    
  0

CRISPR Tools for Gene Editing in the Brain

• Date :
• 0    
  0

Combination Oncolytic Viral and Cellular Therapies to Improve Solid Tumor CART Efficacy

• Date :
• 0    
  0

Combination Local Oncolytic Adenoimmunotherapy and Systemic CAR T-cell Therapies for Solid Tumors

• Date :
• 0    
  0

Clinical Development of NK Cell Cancer Therapy

• Date :
• 0    
  0

Engineered iPSCs to Model Human Leukemia

• Date :
• 0    
  0

CAR T Immunotherapies-Engineering Cell Fitness: TET2-disrupted CAR T cells

• Date :
• 0    
  0

CAR T cells

• Date :
• 0    
  0

Basics of AAV Gene Therapy

• Date :
• 0    
  0

Base Editing Chemistry on a Target Nucleotide in the Genome of Living Cells

• Date :
• 0    
  0

Base Editing Therapeutics Targeted-Nucleotide Editing

• Date :
• 0    
  0

Automated and Decentralized CAR-T cell Manufacturing using Lentiviral vectors

• Date :
• 0    
  0

Antisense Strategies Against Non-Liver Targets

• Date :
• 0    
  0

AAV Vector Manufacturing and Analytics

• Date :
• 0    
  0

AAV Engineering

• Date :
• 0    
  0

Going Viral with Cancer Immunotherapy

• Date :
• 0    
  0

Investigating the Relationship between the Host Cell Transcriptome and Transfection Efficiency

• Date :
• 0    
  0

Lentivirus-mediated Gene Transfer in Stem Cells for Correction of Cystic Fibrosis Defect in Airway

• Date :
• 0    
  0

IRB and Patient Safety - 5 Things You Must Know to Start a Human Gene Therapy Trial

• Date :
• 0    
  0

In Utero Gene Therapy

• Date :
• 0    
  0

Impacts of the Right to Try Laws

• Date :
• 0    
  0

Immunological Considerations of rAAV Gene Therapy

• Date :
• 0    
  0

HSPC Therapies - Engineering Cell Fitness: Enhancing HSPC Homing and Engraftment

• Date :
• 0    
  0

Hematopoietic Stem Cell Gene Therapy and Lysosomal Cross Correction for Cystinosis

• Date :
• 0    
  0

Harnessing Naturaland Engineered Properties of iNKT cells for Adoptive Cancer Immunotherapy

• Date :
• 0    
  0

Local scAAV.IL-1Ra Delivery for Osteoarthritis in an Equine Model: Long Term Safety and Efficacy

• Date :
• 0    
  0

Getting to a Phase I Trial

• Date :
• 0    
  0

Generation of Hematopoietic Stem and Progenitor Cells from iPSCs

• Date :
• 0    
  0

Gene Therapy Using Lentiviral Vector Mediated Gene Addition - An Update from the Clinic

• Date :
• 0    
  0

Gene Modification of Hematopoietic Stem Cells for the Research and Treatment of Hemoglobinopathies

• Date :
• 0    
  0

Gene Editing for DMD

• Date :
• 0    
  0

Gene Editing and Targeted Gene Expression Manipulation for Treating Neurological Disorders

• Date :
• 0    
  0

FDA's Programs to Promote Patient Access to Investigational Therapies

• Date :
• 0    
  0

FDA Regulation of Cell and Gene Therapies: Facilitating Advanced Manufacturing

• Date :
• 0    
  0

Epigenetic Reprogramming Within Tumor Microenvironment Impacts Immune-mediated Gene Therapy Efficacy

• Date :
• 0    
  0

13ème Assises de Génétiques Humaine et Médicale 2025

• Date :
• 693    
  0

ASHG Conférence Annuelle 2025

• Date :
• 1354    
  0

28ème Congrès annuel de l'American Society of Gene & Cell Therapy - ASGCT 2025

• Date :
• 958    
  0

51ème Congrès Annule de l'EBMT

• Date :
• 1040    
  0

Empowering patients 2025 : un sommet de l'American Society of Gene and Cell Therapies – ASGCT 2025

• Date :
• 688    
  0